XML 13 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 25, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Trading Symbol ALNA    
Entity Registrant Name Allena Pharmaceuticals, Inc.    
Entity Central Index Key 0001624658    
Current Fiscal Year End Date --12-31    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period true    
Entity Shell Company false    
ICFR Auditor Attestation Flag false    
Entity Common Stock, Shares Outstanding   89,774,309  
Entity Public Float     $ 76,417,879
Entity Interactive Data Current Yes    
Document Annual Report true    
Document Transition Report false    
Entity File Number 001-38268    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 45-2729920    
Entity Address, Address Line One One Newton Executive Park    
Entity Address, Address Line Two Suite 202    
Entity Address, City or Town Newton    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02462    
City Area Code 617    
Local Phone Number 467-4577    
Title of 12(b) Security Common Stock, par value $0.001 per share    
Security Exchange Name NASDAQ    
Documents Incorporated by Reference

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K.

   
Auditor Name Ernst & Young LLP    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 42